Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)
| Status: | Completed |
|---|---|
| Conditions: | Women's Studies |
| Therapuetic Areas: | Reproductive |
| Healthy: | No |
| Age Range: | 18 - 45 |
| Updated: | 6/27/2018 |
| Start Date: | October 3, 2014 |
| End Date: | October 4, 2016 |
A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Determine the Efficacy and Safety of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis.
A double-blind, phase 3 study to determine the efficacy of SPL7013 Gel when administered on
alternate days for 16 weeks, compared to placebo gel in preventing the recurrence of BV in
women with a history of recurrent BV.
alternate days for 16 weeks, compared to placebo gel in preventing the recurrence of BV in
women with a history of recurrent BV.
Eligible participants, with both a history of recurrent BV and a current episode of BV, will
receive a seven-day course of oral metronidazole. Participants who are successfully treated
for their BV, and continue to be eligible, will be randomly assigned to receive either 1%
SPL7013 Gel or placebo gel on alternate days at bed-time for 16 consecutive weeks.
The primary endpoint will be determined at the conclusion of this 16 week treatment phase.
Participants who experience a BV recurrence will be considered to have completed the study.
Such participants will receive BV treatment in line with local practice and will not attend
any further study visits.
Participants who successfully reach Week 16 without a BV recurrence will enter a 12-week
follow-up phase to Week 28.
Participants will attend a study visit at 4-weekly intervals throughout the duration of the
study to Week 28 (or up to the point of BV recurrence) to assess recurrence of BV and adverse
events.
receive a seven-day course of oral metronidazole. Participants who are successfully treated
for their BV, and continue to be eligible, will be randomly assigned to receive either 1%
SPL7013 Gel or placebo gel on alternate days at bed-time for 16 consecutive weeks.
The primary endpoint will be determined at the conclusion of this 16 week treatment phase.
Participants who experience a BV recurrence will be considered to have completed the study.
Such participants will receive BV treatment in line with local practice and will not attend
any further study visits.
Participants who successfully reach Week 16 without a BV recurrence will enter a 12-week
follow-up phase to Week 28.
Participants will attend a study visit at 4-weekly intervals throughout the duration of the
study to Week 28 (or up to the point of BV recurrence) to assess recurrence of BV and adverse
events.
Inclusion Criteria:
- Current active episode of BV (diagnosis defined as: at least 3 Amsel criteria; Nugent
score of at least 4; presence of BV-related symptoms)
- History of recurrent BV (at least 3 episodes in previous year including current
episode)
- Using an effective method of contraception
Exclusion Criteria:
- Test positive for a sexually transmitted infection
- Presence of genital Herpes Simplex Virus (HSV) lesions or Human Papilloma Virus (HPV)
lesions requiring treatment
- Abnormal pelvic exam, including presence of other vaginal or urinary tract infections
- Pregnancy
We found this trial at
5
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials